David Fandrei

Feb 21, 2025 | nature.com | Maximilian Merz |David Fandrei |Eva Heger |Viola Schweinsberg |Uwe Platzbecker |Michael Hallek | +3 more

AbstractChimeric antigen receptor (CAR) T cells and bispecific T cell engagers have become integral components in the treatment of relapsed/refractory multiple myeloma. We report a 63-year-old male who received ciltacabtagene autoleucel CAR T cells and the GPRC5D × CD3 bispecific talquetamab for early relapse of his multiple myeloma. Nine months after CAR T therapy, he developed a symptomatic leukemic peripheral T cell lymphoma with cutaneous and intestinal involvement.

Dec 4, 2024 | nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more

AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.

Dec 4, 2024 | nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more

AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.

Dec 20, 2023 | nature.com | Rathana Kim |Karl Balabanian |Antoine Toubert |Nicolas Dulphy |Lionel Ades |David Fandrei

To the editor:Myelodysplastic neoplasms (MDS) are hematopoietic stem cell (HSC) disorders arising in the bone marrow (BM) from clonal outgrowth, with the successive acquisition of genetic lesions. MDS are characterized by ineffective hematopoiesis leading to persistent cytopenia affecting one or more hematopoietic lineages, dysplasia, and an increased risk of transformation to acute myeloid leukemia (AML) [1].